How to use Vyloy (zolbetuximab-clzb)

Vyloy (zolbetuximab-clzb), in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are Claudin (CLDN) 18.2 positive in a validated test.

Vyloy for injection is a sterile, preservative-free white to off-white lyophilized powder packaged in single-dose vials, each containing 100 mg of Vyloy . Before starting treatment, physicians will select patients with locally advanced unresectable or metastatic disease

Vyloy is administered in combination with fluoropyrimidine- and platinum-containing chemotherapy as follows: the first intravenous dose is 800 mg/m2 (mg/m2); subsequent intravenous doses are 600 mg/m2 intravenously every 3 weeks, or 400 mg/m2 every 2 weeks, and treatment is continued until disease progression or unacceptable toxicity occurs. If VYLOY and fluoropyrimidine- and platinum-containing chemotherapy are given on the same day, Vyloy must be given first.

If a patient experiences nausea and/or vomiting before taking Vyloy, symptoms should be alleviated to ≤Grade 1 before the first infusion. Before each infusion of Vyloy, patients should be premedicated with antiemetics (such as NK-1 receptor blockers and/or 5-HT3 receptor blockers, and other prescribed medications) to prevent nausea and vomiting. Reducing the dosage of Vyloy is not recommended.